Current level of evidence on causal association between hepatitis C virus and type 2 diabetes: A review
The association between hepatitis C virus (HCV) infection and type 2 diabetes (T2D) has been known for over 20 years. Cross-sectional and longitudinal studies have shown a higher prevalence and incidence, respectively, of T2D in patients with chronic HCV infection. HCV induces glucose metabolism alt...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2017-03-01
|
Series: | Journal of Advanced Research |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2090123216301035 |
id |
doaj-c4bfec6a9703439ead884f05b3666fae |
---|---|
record_format |
Article |
spelling |
doaj-c4bfec6a9703439ead884f05b3666fae2020-11-24T23:19:34ZengElsevierJournal of Advanced Research2090-12322090-12242017-03-018214915910.1016/j.jare.2016.11.003Current level of evidence on causal association between hepatitis C virus and type 2 diabetes: A reviewGiacomo Gastaldi0Nicolas Goossens1Sophie Clément2Francesco Negro3Divisions of Endocrinology, Diabetology, Hypertension and Nutrition, Geneva University Hospitals, Rue Gabrielle Perret-Gentil, 1211 Genève 14, SwitzerlandGastroenterology and Hepatology, Geneva University Hospitals, Rue Gabrielle Perret-Gentil, 1211 Genève 14, SwitzerlandClinical Pathology, Geneva University Hospitals, Rue Gabrielle Perret-Gentil, 1211 Genève 14, SwitzerlandGastroenterology and Hepatology, Geneva University Hospitals, Rue Gabrielle Perret-Gentil, 1211 Genève 14, SwitzerlandThe association between hepatitis C virus (HCV) infection and type 2 diabetes (T2D) has been known for over 20 years. Cross-sectional and longitudinal studies have shown a higher prevalence and incidence, respectively, of T2D in patients with chronic HCV infection. HCV induces glucose metabolism alterations mostly interfering with the insulin signaling chain in hepatocytes, although extrahepatic mechanisms seem to contribute. Both IR and T2D accelerate the histological and clinical progression of chronic hepatitis C as well as the risk of extra-hepatic complications such as nephropathy, acute coronary events and ischemic stroke. Before the availability of direct-acting antivirals (DAAs), the therapeutic choice was limited to interferon (IFN)-based therapy, which reduced the incidence of the extra-hepatic manifestations but was burdened with several contraindications and poor tolerability. A better understanding of HCV-associated glucose metabolism derangements and their reversibility is expected with the use of DAAs.http://www.sciencedirect.com/science/article/pii/S2090123216301035HCVDiabetesInsulin resistanceInflammationSteatosisDirect-acting antivirals |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Giacomo Gastaldi Nicolas Goossens Sophie Clément Francesco Negro |
spellingShingle |
Giacomo Gastaldi Nicolas Goossens Sophie Clément Francesco Negro Current level of evidence on causal association between hepatitis C virus and type 2 diabetes: A review Journal of Advanced Research HCV Diabetes Insulin resistance Inflammation Steatosis Direct-acting antivirals |
author_facet |
Giacomo Gastaldi Nicolas Goossens Sophie Clément Francesco Negro |
author_sort |
Giacomo Gastaldi |
title |
Current level of evidence on causal association between hepatitis C virus and type 2 diabetes: A review |
title_short |
Current level of evidence on causal association between hepatitis C virus and type 2 diabetes: A review |
title_full |
Current level of evidence on causal association between hepatitis C virus and type 2 diabetes: A review |
title_fullStr |
Current level of evidence on causal association between hepatitis C virus and type 2 diabetes: A review |
title_full_unstemmed |
Current level of evidence on causal association between hepatitis C virus and type 2 diabetes: A review |
title_sort |
current level of evidence on causal association between hepatitis c virus and type 2 diabetes: a review |
publisher |
Elsevier |
series |
Journal of Advanced Research |
issn |
2090-1232 2090-1224 |
publishDate |
2017-03-01 |
description |
The association between hepatitis C virus (HCV) infection and type 2 diabetes (T2D) has been known for over 20 years. Cross-sectional and longitudinal studies have shown a higher prevalence and incidence, respectively, of T2D in patients with chronic HCV infection. HCV induces glucose metabolism alterations mostly interfering with the insulin signaling chain in hepatocytes, although extrahepatic mechanisms seem to contribute. Both IR and T2D accelerate the histological and clinical progression of chronic hepatitis C as well as the risk of extra-hepatic complications such as nephropathy, acute coronary events and ischemic stroke. Before the availability of direct-acting antivirals (DAAs), the therapeutic choice was limited to interferon (IFN)-based therapy, which reduced the incidence of the extra-hepatic manifestations but was burdened with several contraindications and poor tolerability. A better understanding of HCV-associated glucose metabolism derangements and their reversibility is expected with the use of DAAs. |
topic |
HCV Diabetes Insulin resistance Inflammation Steatosis Direct-acting antivirals |
url |
http://www.sciencedirect.com/science/article/pii/S2090123216301035 |
work_keys_str_mv |
AT giacomogastaldi currentlevelofevidenceoncausalassociationbetweenhepatitiscvirusandtype2diabetesareview AT nicolasgoossens currentlevelofevidenceoncausalassociationbetweenhepatitiscvirusandtype2diabetesareview AT sophieclement currentlevelofevidenceoncausalassociationbetweenhepatitiscvirusandtype2diabetesareview AT francesconegro currentlevelofevidenceoncausalassociationbetweenhepatitiscvirusandtype2diabetesareview |
_version_ |
1725578285808615424 |